Gelagen Publishes Guide to Korean Gelatin Recipe for Skin and Korean Gummies Ingredients

MDGL Investigation Reminder: Madrigal Pharmaceuticals, Inc. Investors are Encouraged to Contact Kessler Topaz Meltzer & Check, LLP

Minister Olszewski highlights Budget 2026's plan to end homelessness within 10 years

FRVO Investor News: If You Have Suffered Losses in Fervo Energy Company, You Are Encouraged to Contact The Rosen Law Firm About Your Rights

VapoLung Spray Introduces Vapo Lung, a Multi-Ingredient Dietary Supplement for Respiratory Wellness

Routine Invasive Procedures for Stable Heart Disease Offer No Long-Term Survival Advantage Over Drug Therapy

Minister Valdez highlights Budget 2026's plan to end homelessness within 10 years

SodaPeak Releases New Details About Soda Peak Gummies and Their Ingredients

What to Look for in an Online GLP-1 Provider: Meant Outlines Five Questions Worth Asking Before Signing Up

Minister Dabrusin highlights Budget 2026's plan to end homelessness within 10 years

BETR SHAREHOLDER NOTICE: Better Home & Finance Holding Company Investors with Substantial Losses Have Opportunity to Lead Securities...

Notice of AUR Investigation: Kessler Topaz Meltzer & Check, LLP Encourages Aurora Innovation, Inc. (AUR) Investors to Contact the Firm

APP 9-DAY DEADLINE ALERT: AppLovin Corporation Investors with Substantial Losses Encouraged to Contact Hagens Berman, Securities Class...

FuelCell (FCEL) Scrutinized Over Fit Energy Disclosures Driving Stock Down 15% - Hagens Berman

LINC SHAREHOLDER NOTICE: Lincoln Educational Services Corp. Investors with Substantial Losses Have Opportunity to Lead the LINC Securities...

Minister LeBlanc highlights Budget 2026's plan to end homelessness within 10 years

Reyal Design Launches Rebrand and Website Refresh in Margate

Johnson & Johnson announces new Phase 2 nipocalimab study data in Sjögren's disease that reveal insights on importance of symptom...

Johnson & Johnson announces ICOTYDE® (icotrokinra) delivers significant improvement in psoriatic arthritis disease activity among...

argenx Presents Phase 3 ALKIVIA Data at ACR Convergence 2026 Showing Rapid and Sustained Improvement with Efgartigimod in Autoimmune...